Notices. Notice of Grant Awards

5,544 words·~25 min read·/register/2008/01/28/08-299

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4184-01-M DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Awards to Eleven Office of Refugee Resettlement Shelter Care Providers AGENCY: Office of Refugee Resettlement, Administration for Children and Families, HHS. ACTION: Notice of Grant Awards. CFDA #: 93.676 SUMMARY: This notice is hereby given that an award will be made to an unaccompanied alien shelter care provider, Southwest Regional Youth Village, Vincennes, Indiana, in the amount of $586,719.

This funding will support services through September 30, 2008. This funding will support the expansion of secure program bed capacity to meet the number of unaccompanied alien children referrals from the Department of Homeland Security (DHS). The program is mandated by section 462 of the Homeland Security Act to ensure appropriate placement of all referrals from the DHS. ORR's ability to meet this mandate is often a challenge since the program is completely tied to DHS interior apprehension strategies and the sporadic number of border crossers.

The program has very specific requirements for the provision of services. This grantee is one of the only entities with the infrastructure, licensing, experience and appropriate level of trained staff to meet the service requirements for secure capacity. The program's ability to meet the number of secure referrals from DHS can only be accommodated through the expansion of this program through the supplemental award process. FOR FURTHER INFORMATION CONTACT: Kenneth Tota, Office of Refugee Resettlement, Administration for Children and Families, 370 L'Enfant Promenade, SW., Washington, DC, 20447, telephone

(202)401-4858. Dated: January 17, 2008. Brent Orrell, Acting Director, Office of Refugee Resettlement. [FR Doc. E8-1360 Filed 1-25-08; 8:45 am] BILLING CODE 4184-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2008N-0019] Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Survey of Food Safety and Nutrition Information Provided to Pregnant Women by Health Care Providers and the Special Supplemental Nutrition Program for Women, Infants, and Children Educators AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)is announcing that a collection of information entitled “Survey of Food Safety and Nutrition Information Provided to Pregnant Women by Health Care Providers and WIC Educators” has been approved by the Office of Management and Budget

(OMB)under the Paperwork Reduction Act of 1995. FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief Information Officer (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4659. SUPPLEMENTARY INFORMATION: In the **Federal Register** of March 20, 2007 (72 FR 13117), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0617. The approval expires on January 31, 2011. A copy of the supporting statement for this information collection is available on the Internet at *http://www.reginfo.gov/public/do/PRAMain* . Dated: January 18, 2008. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E8-1353 Filed 1-25-08; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2008N-0018] Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Food and Drug Administration Survey of Physicians' Perceptions of the Impact of Early Risk Communication About Medical Products AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)is announcing that a collection of information entitled “FDA Survey of Physicians' Perceptions of the Impact of Early Risk Communication About Medical Products” has been approved by the Office of Management and Budget

(OMB)under the Paperwork Reduction Act of 1995. FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief Information Officer (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4659. SUPPLEMENTARY INFORMATION: In the **Federal Register** of July 19, 2007 (72 FR 39628), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910-0615. The approval expires on December 31, 2010. A copy of the supporting statement for this information collection is available on the Internet at *http://www.reginfo.gov/public/do/PRAMain* . Dated: January 18, 2008. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E8-1355 Filed 1-25-08; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2008N-0017] Agency Information Collection Activities; Proposed Collection; Comment Request; Exports: Notification and Recordkeeping Requirements AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the notification and recordkeeping requirements for persons exporting human drugs, biological products, devices, animal drugs, food, and cosmetics that may not be marketed or sold in the United States. DATES: Submit written or electronic comments on the collection of information by March 28, 2008. ADDRESSES: Submit electronic comments on the collection of information to: *http://www.regulations.gov* . Submit written comments on the collection of information to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief Information Officer (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4659. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget

(1)Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility;

(2)the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3)ways to enhance the quality, utility, and clarity of the information to be collected; and

(4)ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Exports: Notification and Recordkeeping Requirements, 21 CFR Part 1 (OMB Control Number 0910-0482) — Extension The respondents to this information collection are exporters who have notified FDA of their intent to export unapproved products that may not be sold or marketed in the United States as allowed under 801(e) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 381). In general, the notification identifies the product being exported (e.g. name, description, and in some cases, country of destination) and specifies where the notification should be sent. These notifications are sent only for an initial export; subsequent exports of the same product to the same destination (or, in the case of certain countries identified in section 802(b) of the act (21 U.S.C. 382), to any of those countries would not result in a notification to FDA. The recordkeepers to this information collection are exporters who export human drugs, biologics, devices animal drugs, foods and cosmetics that may not be sold in the United States to maintain records demonstrating their compliance with the requirements in section 801(e)

(1)of the act. The total burden estimate of 39,120 is based on the number of notifications received by the relevant FDA centers in fiscal year 2007, or the last year the figures available. FDA estimates the burden of this collection of information as follows: **Table 1.—Estimated Annual Reporting Burden** 1 21 CFR Section No. of Respondents Annual Frequency per Response Total Annual Responses Hours per Response Total Hours 1.101 (d)-(e) 400 3 1200 15 18,000 1 There are no capital costs or operating and maintenance costs associated with this collection of information. **Table 2.—Estimated Annual Recordkeeping Burden** 1 21 CFR Section No. of Recordkeepers Annual Frequency of Recordkeeping Total Annual Records Hours per Recordkeeper Total Hours **1.101 (b)-(c)** 320 3 960 22 21,120 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Please note that on January 15, 2008, the FDA Web site transitioned to the Federal Dockets Management System (FDMS). FDMS is a Government-wide, electronic docket management system. Electronic submissions will be accepted by FDA through FDMS only. Dated: January 18, 2008. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E8-1356 Filed 1-25-08; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2008-D-0030] (formerly Docket No. 2004D-0466) Agency Information Collection Activities; Proposed Collection; Comment Request; Draft Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under the Federal Food, Drug, and Cosmetic Act AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration

(FDA)is announcing an opportunity for public comment on the proposed collection of certain information by the agency. Under the Paperwork Reduction Act of 1995 (the PRA), Federal agencies are required to publish notice in the **Federal Register** concerning each proposed collection of information and to allow 60 days for public comment in response to the notice. This notice solicits comments on the information collection provisions of the draft guidance entitled “Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act.” DATES: Submit written or electronic comments on the collection of information by March 28, 2008. ADDRESSES: Submit electronic comments on the collection of information to: *http://www.regulations.gov* . Submit written comments on the collection of information to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief Information Officer (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-4659. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal agencies must obtain approval from the Office of Management and Budget

(OMB)for each collection of information they conduct or sponsor. “Collection of information” is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal agencies to provide a 60-day notice in the **Federal Register** concerning each proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, in the **Federal Register** of November 9, 2004 (69 FR 64962), FDA published a notice of availability of the draft guidance document providing a 60-day public comment period on the collection of information provisions. Thereafter, in the **Federal Register** of June 7, 2007 (72 FR 31583), FDA published a 30-day notice responding to comments on the collection of information provisions received in response to the November 9, 2004, notice and announcing that the proposed collection of information had been submitted to OMB. In response to a request by OMB, FDA is republishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics:

(1)Whether the proposed collection of information is necessary for the proper performance of FDA's functions, including whether the information will have practical utility;

(2)the accuracy of FDA's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;

(3)ways to enhance the quality, utility, and clarity of the information to be collected; and

(4)ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Substantiation for Dietary Supplement Claims Made Under Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (OMB Control Number 0910—NEW) Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 343(r)(6)) requires that a manufacturer of a dietary supplement making a nutritional deficiency, structure/function, or general well-being claim have substantiation that the statement is truthful and not misleading. The draft guidance document entitled “Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r)(6) of the Federal Food, Drug, and Cosmetic Act” is intended to describe the amount, type, and quality of evidence FDA recommends a dietary supplement manufacturer have to substantiate a claim under section 403(r)(6) of the act. This draft guidance does not discuss the types of claims that can be made concerning the effect of a dietary supplement on the structure or function of the body, nor does it discuss criteria to determine when a statement about a dietary supplement is a disease claim. Persons with access to the Internet may obtain the draft guidance at the following Web site: *http://www.cfsan.fda.gov/~dms/guidance.html* . A copy of the draft guidance also is available for public examination in the Division of Dockets Management (see ADDRESSES ). FDA estimates the burden of this collection of information as follows: **Table 1.—Estimated Annual Reporting Burden** 1 Claim Type No. of Respondents Annual Frequency per Response Total Annual Responses Hours per Response Total Hours Widely known, established 667 1 667 44 29,348 Pre-existing, not widely established 667 1 667 120 80,040 Novel 667 1 667 120 80,040 Total 189,428 1 There are no capital costs or operating and maintenance costs associated with this collection of information. Dietary supplement manufacturers will only need to collect information to substantiate their product's nutritional deficiency, structure/function, or general well-being claim if they chose to place a claim on their product's label. Gathering evidence on their product's claim is a one time burden; they collect the necessary substantiating information for their product as required by section 403(r)(6) of the act. The standard discussed in the draft guidance for substantiation of a claim on the labeling of a dietary supplement is consistent with standards set by the Federal Trade Commission for dietary supplements and other health-related products that the claim be based on competent and reliable scientific evidence. This evidence standard is broad enough that some dietary supplement manufacturers may only need to collect peer-reviewed scientific journal articles to substantiate their claims; other dietary supplement manufacturers whose products have properties that are less well documented may have to conduct studies to build a body of evidence to support their claims. It is unlikely that a dietary supplement manufacturer will attempt to make a claim when the cost of obtaining the evidence to support the claim outweighs the benefits of having the claim on the product's label. It is likely that manufacturers will seek substantiation for their claims in the scientific literature. The time it takes to assemble the necessary scientific information to support their claims depends on the product and the claimed benefits. If the product is one of several on the market making a particular claim for which there is adequate publicly available and widely established evidence supporting the claim, then the time to gather supporting data will be minimal; if the product is the first of its kind to make a particular claim or the evidence supporting the claim is less publicly available or not widely established, then gathering the appropriate scientific evidence to substantiate the claim will be more time consuming. FDA assumes that it will take 44 hours to assemble information needed to substantiate a claim on a particular dietary supplement when the claim is widely known and established. We increased this estimated burden from 1 hour per claim to 44 hours per claim based on information received from industry, as noted in our June 7, 2007, notice in response to comment 1 (72 FR 31583 and 31584). FDA believes it will take closer to 120 hours to assemble supporting scientific information when the claim is novel or when the claim is pre-existing but the scientific underpinnings of the claim are not widely established. These are claims that may be based on emerging science, where conducting literature searches and understanding the literature takes time. It is also possible that references for claims made for some dietary ingredients or dietary supplements may primarily be found in foreign journals and in foreign languages or in the older, classical literature where it is not available on computerized literature databases or in the major scientific reference databases, such as the National Library of Medicine's literature database, all of which increases the time of obtaining substantiation. In the **Federal Register** of January 6, 2000, FDA published a final rule on statements made for dietary supplements concerning the effect of the product on the structure or function of the body (65 FR 1000). FDA estimated that there were 29,000 dietary supplement products marketed in the United States (65 FR 1000 at 1045). Assuming that the flow of new products is 10 percent per year, then 2,900 new dietary supplement products will come on the market each year. The structure/function final rule estimated that about 69 percent of dietary supplements have a claim on their labels, most probably a structure/function claim (65 FR 1000 at 1046). Therefore, we assume that supplement manufacturers will need time to assemble the evidence to substantiate each of the 2,001 claims (2,900 x 69 percent) made each year. If we assume that the 2,001 claims are equally likely to be pre-existing widely established claims, novel claims, or pre-existing claims that are not widely established, then we can expect 667 of each of these types of claims to be substantiated per year. Table 1 of this document shows that the annual burden hours associated with assembling evidence for claims is 189,428 (the sum of 667 x 44 hours, 667 x 120 hours, and 667 x 120 hours). There are no capital costs or operating and maintenance costs associated with this information collection. Please note that on January 15, 2008, the FDA Web site transitioned to the Federal Dockets Management System (FDMS). FDMS is a Government-wide, electronic docket management system. Electronic submissions will be accepted by FDA through FDMS only. Dated: January 18, 2008. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E8-1362 Filed 1-25-08; 8:45 am] BILLING CODE 4160-01-S DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration National Advisory Council on the National Health Service Corps AGENCY: Health Resources and Services Administration, HHS. ACTION: Correction of meeting date. SUMMARY: The Health Resources and Services Administration published a meeting notice for the National Advisory Council on the National Health Service Corps in the **Federal Register** of January 15, 2008 (FR Doc. E8-581), on page 2510. The beginning date of the meeting has changed. Correction In the **Federal Register** issue of January 15, 2008, (FR Doc. E8-581), on page 2510 under the category Dates and Times, the new meeting dates are February 29, 2008, 8:30 a.m.-5 p.m. and March 1, 2008, 9 a.m.-5 p.m. Dated: January 22, 2008. Alexandra Huttinger, Acting Director, Division of Policy Review and Coordination. [FR Doc. E8-1371 Filed 1-25-08; 8:45 am] BILLING CODE 4165-15-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Health Resources and Services Administration Statement of Organization, Functions and Delegations of Authority This notice amends Part R of the Statement of Organization, Functions and Delegations of Authority of the Department of Health and Human Services (HHS), Health Resources and Services Administration

(HRSA)(60 FR 56605-56606 as amended November 6, 1995; and as last amended at 72 FR 57588-57589, dated October 10, 2007.) This notice reflects organizational changes in the Health Resources and Services Administration, Office of the Administrator, Office of Communications (RA6). Specifically, this notice updates the functional statement of the Office of the Administrator, Office of Communications (RA6). Chapter RA, Office of the Administrator Section RA-10, Organization The Offices under the Immediate Office of the Administrator consist of the following components:

(1)Immediate Office of the Administrator (RA);

(2)Office of Equal Opportunity and Civil Rights (RA2);

(3)Office of Planning and Evaluation (RA5);

(4)Office of Communications (RA6);

(5)Office of Minority Health and Health Disparities (RA9);

(6)Office Legislation (RAE);

(7)Office of Information Technology (RAG); and

(8)Office of International Health Affairs (RAH). Section RA-20, Functions Delete the functional statement for the Office of Communications

(RA6)in its entirety and replace it with the following: Office of Communications

(1)Provides leadership and coordinates communications and public affairs activities for the Agency;

(2)coordinates Agency communications activities with those of other health agencies within the Department of Health and Human Services and with field, State, local, voluntary, and professional organizations;

(3)develops and implements national communications initiatives to inform and educate the public, health care professionals, policy makers, and the media;

(4)coordinates, researches, writes and prepares speeches and audiovisual presentations for the HRSA Administrator and other senior HRSA staff;

(5)provides communication and public affairs expertise to the Agency consistent with policy direction established by the HHS Assistant Secretary for Public Affairs;

(6)develops, obtains clearance for, and publicizes press releases and media briefs, fact sheets and other news and information items describing Agency programs and services;

(7)serves as Communications and Public Affairs Officer for the Agency including establishment and maintenance of productive relationships with the news media;

(8)reviews and edits all Agency publications and promotional materials and oversees all Agency exhibits;

(9)handles all public requests for release of HRSA information and records under the Freedom of Information Act;

(10)manages the Agency Web information content, function, and design and leads the development of Agency Internet content policies; and

(11)manages audio visual and multimedia activities in support of Agency communication efforts. Section RC-30, Delegations of Authority All delegations of authority and re-delegations of authority made to HRSA officials that were in effect immediately prior to this reorganization, and that are consistent with this reorganization, shall continue in effect pending further re-delegation. This reorganization is effective upon the date of signature. Dated: January 15, 2008. Elizabeth M. Duke, Administrator. [FR Doc. E8-1370 Filed 1-25-08; 8:45 am] BILLING CODE 4165-15-P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. *Name of Committee:* Cardiovascular Sciences Integrated Review Group, Clinical and Integrative Cardiovascular Sciences Study Section. *Date:* February 7-8, 2008. *Time:* 8 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* The Fairmont Washington, DC, 2401 M Street, NW., Washington, DC 20037. *Contact Person:* Russell T. Dowell, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4128, MSC 7814, Bethesda, MD 20892,

(301)435-1850, *dowellr@csr.nih.gov* . This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. *Name of Committee:* Genes, Genomes, and Genetics Integrated Review Group, Ethical, Legal, and Social Implications of Human Genetics Study Section. *Date:* February 13-14, 2008. *Time:* 8 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting) *Contact Person:* Cheryl M. Corsaro, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 2204, MSC 7890, Bethesda, MD 20892,

(301)435-1045, *corsaroc@csr.nih.gov* . *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Vascular Biology. *Date:* February 14, 2008. *Time:* 8 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications and/or proposals. *Place:* Holiday Inn Georgetown, 2101 Wisconsin Avenue, NW., Washington, DC 20007. *Contact Person:* Bukhtiar H. Shah, DVM, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4095J, MSC 7822, Bethesda, MD 20892,

(301)435-1233, *shahb@csr.nih.gov* . *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Innovative Ultrasound and Imaging. *Date:* February 18, 2008. *Time:* 8 a.m. to 12 p.m. *Agenda:* To review and evaluate grant applications. *Place:* Bahia Resort Hotel, 998 West Mission Bay Drive, San Diego, CA 92109. *Contact Person:* Antonio Sastre, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5215, MSC 7412, Bethesda, MD 20892,

(301)435-2592, *sastrea@csr.nih.gov* . *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Electromagnetic Devices. *Date:* February 18, 2008. *Time:* 4 p.m. to 7 p.m. *Agenda:* To review and evaluate grant applications. *Place:* Bahia Resort Hotel, 998 West Mission Bay Drive, San Diego, CA 92109. *Contact Person:* Antonio Sastre, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5215, MSC 7412, Bethesda, MD 20892,

(301)435-2592, *sastrea@csr.nih.gov* . *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Cancer Diagnostics and Treatments I SBIR/STTR. *Date:* February 20-21, 2008. *Time:* 11 a.m. to 7 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting) *Contact Person:* Hungyi Shau, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892, 301-435-1720, *shauhung@cfr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Cancer Diagnostics and Treatments II SBIR/STTR. *Date:* February 20, 2008. *Time:* 11 a.m. to 7 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting) *Contact Person:* Hungyi Shau, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892, 301-435-1720, *shauhung@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Cancer Genetics and Genomics SEP. *Date:* February 20, 2008. *Time:* 3 p.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call) *Contact Person:* Steven B. Scholnick, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6152, MSC 7804, Bethesda, MD 20892, 301-435-1719, *scholnis@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Member Conflicts in Cognition, Perception, and Language. *Date:* February 21, 2008. *Time:* 1:30 p.m. to 3 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call) *Contact Person:* Alfonso R. Latoni, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3182, MSC 7848, Bethesda, MD 20892, 301-435-0913, *latonia@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Bioengineering Research Partnerships. *Date:* February 25, 2008. *Time:* 8 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* Ramada Rockville/The Legacy Hotel, 1775 Rockville Pike, Rockville, MD 20852. *Contact Person:* John Firrell, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5213, MSC 7854, Bethesda, MD 20892, 301-435-2598, *firrellj@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Health Promotion Programs for Older Workers SBIR Study Section. *Date:* February 25, 2008. *Time:* 1 p.m. to 3 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call) *Contact Person:* Karin F. Helmers, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3148, MSC 7770, Bethesda, MD 20892, 301-435-1017, *helmersk@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Hypersensitivity, Autoimmune, and Immune-mediated Diseases: Member Conflicts and Overflow. *Date:* February 27-28, 2008. *Time:* 10 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting) *Contact Person:* Stephen M. Nigida, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4212, MSC 7812, Bethesda, MD 20892, 301-435-1222, *nigidas@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Cancer Drug Development and Therapeutics 1 SBIR/STTR. *Date:* February 27-28, 2008. *Time:* 11 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting) *Contact Person:* Hungyi Shau, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892, 301-435-1720, *shauhung@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Member Conflict: Pain and Somatosensory. *Date:* February 28-29, 2008. *Time:* 8 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting) *Contact Person:* Joseph G. Rudolph, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5186, MSC 7844, Bethesda, MD 20892, 301-435-2212, *josephru@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, ZRG1 F09-B

(20)Oncology Fellowship. *Date:* February 28-29, 2008. *Time:* 8 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* The Ritz-Carlton, 1150 22nd Street, NW., Washington, DC 20037. *Contact Person:* Eun Ah Cho, PhD, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6202, MSC 7804, Bethesda, MD 20892,

(301)451-4467, *choe@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Diabetes, Obesity and Nutrition. *Date:* February 28, 2008. *Time:* 10 a.m. to 4 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting) *Contact Person:* Krish Krishnan, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6164, MSC 7892, Bethesda, MD 20892,

(301)435-1041, *krishnak@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Drug Discovery. *Date:* February 28, 2008. *Time:* 11 a.m. to 1 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call) *Contact Person:* Manzoor Zarger, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6208, MSC 7804, Bethesda, MD 20892,

(301)435-2477, *zargerma@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Oncology AREA. *Date:* February 29, 2008. *Time:* 8 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting) *Contact Person:* Lambratu Rahman, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6214, MSC 7804, Bethesda, MD 20892,

(301)451-3493, *rahmanl@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Fellowship: Sensory, Motor and Cognitive Neuroscience. *Date:* February 29, 2008. *Time:* 8 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* Embassy Suites Washington DC, 1250 22nd Street, NW., Washington, DC 20037. *Contact Person:* John Bishop, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 5180, MSC 7844, Bethesda, MD 20892,

(301)435-1250, *bishopj@csr.nih.gov.* *Name of Committee:* Center for Scientific Review Special Emphasis Panel, Radiology Oncology. *Date:* February 29, 2008. *Time:* 11 a.m. to 12 p.m. *Agenda:* To review and evaluate grant applications. *Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Telephone Conference Call) *Contact Person:* Manzoor Zarger, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6208, MSC 7804, Bethesda, MD 20892,

(301)435-2477, *zargerma@csr.nih.gov.* (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS) January 18, 2008. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 08-299 Filed 1-25-08; 8:45 am]

Connectionstraces to 6

Traces to 6 documents

U.S. Code